71610 0198 53
Gabapentin Capsule
Product Images NDC 71610-198
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-198). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Aphena Pharma Solutions (TN)
Figure 1 (Image 01)
This is a table displaying the mean pain score for two treatment methods over a span of weeks. The methods are described as "Parkod" with titration and "Parkod" with a fixed dose. There is also a placebo and Gabapentin treatment option at 3600 mg/day. The baseline pain score is listed as 0 and the study follows the participants for several weeks.*
Figure 2 (Image 02)
This is a graph that represents the 3-week dose titration period, with a 4-week fixed dose period for a placebo and two dosages of Gabapentin (1800mg/day and 2400mg/day). The graph displays the mean pain score over time for the different dosages.*
Figure 3 (Image 03)
Cockcroft And Gault Equation (Image 04)
Gabapentin Structural Formula (Image 05)
Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
